Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial.

JTO Clin Res Rep · 2025 · PMC12745942 · PMID 41473840

Europe PMC DOI

hedged sentence

0.0096

closest p · 0.2× alpha

0.0096

boldest claim

The sentences

highly significantp = 0.0096actually significant

This improvement was highly significant according to the Wilcoxon signed rank test ( p = 0.0096).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.